evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 5 · 83.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

L‐ornithine L‐aspartate vs probiotic

Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with probiotic (very low certainty).

1 finding from 1 review

L‐ornithine L‐aspartate vs rifaximin

Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with rifaximin (very low certainty).

1 finding from 1 review

L‐ornithine L‐aspartate vs lactulose

Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).

1 finding from 1 review

L‐ornithine L‐aspartate vs lactulose

Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).

1 finding from 1 review

L‐ornithine L‐aspartate vs probiotic

Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

The review found no eligible studies for this question.

1 finding from 1 review

L‐ornithine L‐aspartate vs rifaximin

Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…

It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with rifaximin (very low certainty).

1 finding from 1 review